Pharmaceutical company Novo Nordisk is waiting on federal approval to sell its blockbuster GLP-1 weight-loss treatment as a ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

Pop quiz: would you prefer to take a medication as a pill or inject yourself with it? Somehow, I suspect that the vast ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement ...

Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

The U.S. FDA has accepted the NDA for an oral formulation of Novo Nordisk A/S’s Wegovy (semaglutide) in treating obesity. If ...

Weight loss pills either reduce appetite, boost metabolism or block fat absorption. Most people lose 5% to 10% of their body ...

The rise in GLP-1 use among young women raises concerns about contraceptive efficacy and potential pregnancy risks. Learn ...

Nationally representative survey data revealed that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) use for obesity ...